Lack of buprenorphine access for adolescents in residential facilities

Only 1 in 4 residential facilities that treat adolescents in the U.S. for opioid use disorder offer buprenorphine, the sole approved medication for 16- to 18-year-olds.
Source: NIH Research Matters from the National Institutes of Health (NIH) - Category: Consumer Health News Source Type: news